Jennison Associates LLC Has $44.89 Million Stock Position in Natera, Inc. $NTRA

Jennison Associates LLC lowered its holdings in Natera, Inc. (NASDAQ:NTRA - Free Report) by 42.4% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 195,943 shares of the medical research company's stock after selling 144,366 shares during the quarter. Jennison Associates LLC owned 0.14% of Natera worth $44,889,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Trifecta Capital Advisors LLC acquired a new stake in Natera in the 4th quarter valued at approximately $115,000. Moody Aldrich Partners LLC acquired a new stake in shares of Natera during the 4th quarter worth approximately $269,000. Interchange Capital Partners LLC acquired a new stake in shares of Natera during the 4th quarter worth approximately $215,000. M&T Bank Corp grew its holdings in shares of Natera by 76.0% during the 4th quarter. M&T Bank Corp now owns 9,808 shares of the medical research company's stock worth $2,247,000 after purchasing an additional 4,235 shares in the last quarter. Finally, Exencial Wealth Advisors LLC acquired a new stake in shares of Natera during the 4th quarter worth approximately $248,000. Institutional investors and hedge funds own 99.90% of the company's stock.

Natera Price Performance

Natera stock opened at $207.28 on Friday. The business has a 50 day simple moving average of $202.02 and a 200 day simple moving average of $213.75. Natera, Inc. has a one year low of $131.81 and a one year high of $256.36. The company has a market capitalization of $29.50 billion, a PE ratio of -135.48 and a beta of 1.57.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings data on Thursday, February 26th. The medical research company reported $0.35 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.81. Natera had a negative return on equity of 15.28% and a negative net margin of 9.03%.The firm had revenue of $665.50 million during the quarter, compared to the consensus estimate of $600.68 million. During the same quarter in the previous year, the company posted ($0.41) EPS. Equities analysts anticipate that Natera, Inc. will post -1.71 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Natera news, insider John Fesko sold 3,594 shares of Natera stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $231.02, for a total value of $830,285.88. Following the completion of the transaction, the insider owned 178,081 shares in the company, valued at approximately $41,140,272.62. The trade was a 1.98% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Solomon Moshkevich sold 3,000 shares of Natera stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $199.85, for a total value of $599,550.00. Following the completion of the transaction, the insider owned 150,023 shares of the company's stock, valued at approximately $29,982,096.55. The trade was a 1.96% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 138,069 shares of company stock worth $30,896,634. 5.63% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. Wall Street Zen raised Natera from a "hold" rating to a "buy" rating in a report on Saturday, April 18th. Weiss Ratings reissued a "sell (d-)" rating on shares of Natera in a report on Tuesday, April 21st. Wells Fargo & Company lifted their price objective on Natera from $205.00 to $215.00 and gave the stock an "equal weight" rating in a report on Friday, February 27th. Guggenheim lifted their price objective on Natera from $230.00 to $270.00 and gave the stock a "buy" rating in a report on Monday, January 5th. Finally, Citigroup assumed coverage on Natera in a report on Wednesday, January 7th. They set a "buy" rating and a $300.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $253.47.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.